Anona Therapeutics

Anona Therapeutics is a stealth-stage biotechnology company based in Cambridge, Massachusetts, focused on targeting RNA-binding proteins (RBPs) to treat complex diseases. Co-founded by industry pioneers including Melissa Moore, the former CSO of Moderna, and Brent Stockwell, the company is developing a platform that uses small molecules to modulate the transcriptome. This approach aims to regulate the proteome by influencing RNA processing and protein expression, targeting mechanisms that were previously considered undruggable. Anona is currently in the pre-clinical stage and is positioned to address high unmet needs in therapeutic areas such as oncology and neurology with its innovative RNA-targeted discovery engine.